Clinical protocols often fail to keep pace with the latest research. On average, it takes 17 years for new evidence to become standard clinical practice.
In the meantime, 61% of physicians regularly scan social media to understand where science is heading, and 57% say it has already changed their view of medication. A single digital opinion leader (DOL) with millions of followers can influence the prescribing decisions of thousands of HCPs.
By providing DOLs with timely, evidence-based content, pharma has an opportunity to help shape the narratives reaching this audience. The key point is that life sciences brands don’t need to persuade HCPs to engage with DOLs. They are already listening.
Why HCPs Turn to DOLs
HCPs have a legitimate reason to follow DOLs: their patients are becoming more curious and increasingly turning to AI-powered search for answers. Faced with a new diagnosis, many are eager to find reassuring explanations and may trust inaccurate, oversimplified AI responses that reinforce their own hopes and biases.
That leaves physicians responsible for correcting misinformation while delivering care. Timely, medically governed insights from trusted DOLs help them stay on top of the latest evidence and conversations happening online.
Finding the Right DOLs Is an Uphill Climb
Pharma teams lack a structured approach to finding the right DOLs for their campaigns. They often pay attention to a DOL's visibility, mistaking it for influence.
Yet, the process should begin with a clear understanding of campaign objectives, market dynamics, target audience, and therapeutic focus before creating a shortlist of potential collaborators.
Every DOL should be evaluated against clear eligibility criteria (5Rs). Without a strong "resume" (scientific credibility), resonance, relevance, reach, and reliability, brands risk investing in partnerships that won't deliver the outcomes they set out to achieve.
However, meeting all these criteria is easier said than done. Some respected traditional Key Opinion Leaders (KOLs) have little or no digital presence. Some highly visible creators have influence but are not HCPs. Others are active online but rarely discuss the relevant therapeutic area, while some have large audiences that fall outside the target segment. And even candidates who seem like a good fit may publish content that lacks scientific rigor or poses compliance risks.
So, when you find and score your DOLs, the next step is to prioritize them. The score is important, but it is not the only factor. Teams should also consider whether the DOL fits local market goals, whether a partnership is realistic, and whether they have the time and resources to support it.
Like Any Relationship, DOL Relationships Need Nurturing
Finding the right DOL is only one piece of the puzzle. The next step is activating those relationships. The right DOLs already have the audience, clinical credibility, and motivation to communicate evidence accurately. What they often lack is the time and tools to create content consistently and respond in real time.
In practice, that means providing post ideas, pre-approved content kits, and evidence-backed assets they can quickly adapt and share. One way to give a DOL something usable on their timeline is to have the building blocks approved and waiting: modular claims organized by therapeutic area, platform-specific templates, and a clear line back to the approved source for every piece, so both the DOL and the company stay protected.
Finally, resist the temptation to hide promotional intent and be clear about why you’re collaborating. The conversation should be framed as: “We are here to help you share timely, evidence-based information with the HCPs who trust your expertise.”
DOL Engagement Is a Work in Progress
Engaging DOLs is always a continious effort. As Mark Watson, co-founder of Fractal Force, said on the Pharma Talks podcast: “A brand plan and HCP personas are useful, but effective physician engagement depends on understanding what HCPs are thinking right now and what they need today. That is what a real conversation looks like.”
Track audience signals, disease focus, and HCP responses over time. These insights help ensure you’re speaking the same language as your audience when the rubber meets the road.
Monitor posting frequency, audience growth, therapeutic focus, engagement patterns, and changes in content quality or scientific consistency. At the same time, watch for shifts in audience demographics, geography, or compliance risks that may require re-prioritization.
The US Market Moment and Why 2026 is the Right Time to Move
The US is home to one of the world’s most active communities of physicians on platforms like LinkedIn, YouTube, and X. A recent survey of 150 US clinicians found that many use social media to stay aware of new therapies, while podcasts and video content have become common sources of professional education.
At the same time, the US pharma market is highly competitive, with multiple juggernauts competing within the same therapeutic area. When products offer comparable efficacy and safety profiles, pharma teams must invest more heavily in building awareness and educating physicians early in the adoption journey.
Just as the need to educate physicians has grown, access to them has declined. HCP access in the US has fallen from 60% to 45% in recent years due to rising patient volumes, healthcare consolidation, and tighter health system restrictions. With fewer opportunities for in-person engagement, leading brands started to rely on DOLs, helping physicians interpret new evidence, apply it in clinical practice, and counter misinformation online.
Start With the Rules Instead of Search
Before you start searching for DOLs, define the rules of the game. Clarify your objective, target audience, therapy area, market, and preferred digital channels. Those decisions determine who qualifies as a relevant DOL and who simply has a large following.
In practice, the most difficult part is verification. Establish clear criteria around scientific credibility, clinical relevance, reach, reliability, and audience resonance.
And remember: DOLs, social media, market, HCPs, and science are changing over time, so successful programs are always built for long-term monitoring.
The conversation shaping how HCPs think about your therapeutic area is happening either way. The only question is whether pharma's evidence is part of it.
At Viseven, we help brands make sure it is by finding, validating, engaging, and monitoring the DOLs who matter most. If you're exploring DOL engagement and would like a hand, reach out.